Overview of Dr. Galsky
Dr. Matthew Galsky is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice 19 years. Dr. Galsky accepts several types of health insurance, listed below. He is one of 189 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
10 E 102nd St
New York, NY 10029Fax+1 212-423-0522
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1998 - 2001
- Tufts University School of MedicineClass of 1998
Certifications & Licensure
- NY State Medical License 2001 - 2025
- NV State Medical License 2006 - 2011
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
- Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma Start of enrollment: 2010 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 1470 citationsAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak
Lancet. 2017-01-07 - 167 citationsRisk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-AnalysisSonia Seng, Ziyue Liu, Sophia Chiu, Tracy Proverbs-Singh, Guru Sonpavde
Journal of Clinical Oncology. 2012-11-13 - 1157 citationsNivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Margitta Retz, Arlene O. Siefker-Radtke, Ari David Baron, Andrea Necchi
The Lancet. Oncology. 2017-03-01
Journal Articles
- Identification of microR-106b as a Prognostic Biomarker of p53-like Bladder Cancers by ActMiRMatthew D Galsky, William K Oh, Nature
Lectures
- A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in ...2019 ASCO Annual Meeting - 6/1/2019
- Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (m...2019 ASCO Annual Meeting - 6/1/2019
- Is there a difference in PD-1 / PD-L1 inhibitors for urothelial cancer? Continuous Evolution of a Phase I Trial Into An FDA Package2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Authored Content
- PD-1/PD-L1 Inhibition in Bladder Cancer Now and in the Future, Part 1March 2023
Press Mentions
- Immunotherapy After Surgery Is Beneficial for High-Risk Bladder Cancer PatientsApril 3rd, 2023
- CheckMate 274: Continued Disease-Free Survival Benefits with Adjuvant Nivolumab in High-Risk Urothelial CarcinomaMarch 8th, 2023
- CheckMate 274 Follow up Data Boost Nivolumab Potential for High-Risk Bladder CancerMarch 8th, 2023
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: